Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.78 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.78 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | RAB9A | P51151 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | POLB | P06746 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2247414 | 0.98 | ALOX5 (0.76) | ALOX5EPHX2ADORA2ACHEK1LIMK1 | |
| SCHEMBL10758216 | 0.88 | ALOX5 (1.00) | ALOX5EPHX2CHEK1LIMK1CDK5 | |
| SCHEMBL28307753 | 0.80 | MEN1 (0.58) | ALOX5EPHX2ALDH1A1RAB9AKDM4E | |
| SCHEMBL8677683 | 0.79 | F2 (0.54) | ALOX5EPHX2CHEK1LIMK1CDK5 | |
| Fuberidazole SCHEMBL8817074 | 0.79 | ALOX5 (0.65) | ALOX5EPHX2CHEK1LIMK1CDK5 | |
| Fuberidazole SCHEMBL29603252 | 0.79 | ALOX5 (0.65) | ALOX5EPHX2CHEK1LIMK1CDK5 | |
| Fuberidazole SCHEMBL23174 | 0.79 | ALOX5 (0.65) | ALOX5EPHX2CHEK1LIMK1CDK5 | |
| SCHEMBL19228822 | 0.78 | ALOX5 (0.53) | ALOX5EPHX2CHEK1LIMK1CDK5 | |
| SCHEMBL3340524 | 0.78 | ALDH1A1 (0.58) | ALOX5EPHX2CHEK1LIMK1CDK5 | |
| SCHEMBL20550742 | 0.78 | ALOX5 (0.53) | ALOX5EPHX2CHEK1LIMK1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066364-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2025-02-27 | — | — | US | disclosed |
| EP-4406616-A2 | SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2024-07-31 | — | — | EP | disclosed |
| US-11932645-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R & D Investments, S.A. (PT) | 2024-03-19 | — | — | US | disclosed |
| EP-3215510-B1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2023-06-07 | — | — | EP | disclosed |
| CN-115925711-A | Substituted pyrazolo [1,5-a ] pyrimidines and their use in treating medical disorders | BIAL研发投资股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-11400095-B2 | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-08-02 | — | — | US | disclosed |
| US-20220169652-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. | 2022-06-02 | — | — | US | disclosed |
| US-11091492-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-08-17 | — | — | US | disclosed |
| US-20210169886-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-06-10 | — | — | US | disclosed |
| US-20200385390-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2020-12-10 | — | — | US | disclosed |
| US-8362072-B2 | BRCA1-based breast or ovarian cancer treatment agents and methods of use | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120259005-A1 | BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use | UNIVERSITY OF KANSAS (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120259005-A1 | BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use | UNIVERSITY OF KANSAS (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120259005-A1 | BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use | UNIVERSITY OF KANSAS (US) | 2012-10-11 | — | — | US | disclosed |
| US-20090170842-A1 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE | UNIVERSITY OF KANSAS (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170842-A1 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE | UNIVERSITY OF KANSAS (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170842-A1 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE | UNIVERSITY OF KANSAS (US) | 2009-07-02 | — | — | US | disclosed |
| WO-2009065028-A2 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE | UNIVERSITY OF KANSAS (US) | 2009-05-22 | — | — | WO | disclosed |
| US-4716168-A | STIMULANTS OF IMMUNE RESPONSE | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1987-12-29 | — | — | US | disclosed |
| EP-0187705-A2 | Imidazo(4,5-f)quinolines useful as immunomodulating agents | Norwich Eaton Pharmaceuticals, Inc. (US) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259005-A1 | BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use | BRCA1, BRAP, BCCIP | ALOX5 2566/4885EPHX2 4669/4885ADORA2A 3436/4885 |
| US-20090170842-A1 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE | BRCA1, BRAP, BCCIP | ALOX5 2529/4885EPHX2 4647/4885ADORA2A 3411/4885 |
| US-11932645-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | PARK7, PNP, GAA | ALOX5 685/4885EPHX2 3518/4885ADORA2A 203/4885 |
| US-20210169886-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, SNCA | ALOX5 2037/4885EPHX2 3437/4885ADORA2A 187/4885 |
| US-11400095-B2 | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | GBA1, GAA, SNCA | ALOX5 2037/4885EPHX2 3437/4885ADORA2A 187/4885 |
| US-20220169652-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | ALOX5 685/4885EPHX2 3518/4885ADORA2A 203/4885 |
| US-20200385390-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | ALOX5 685/4885EPHX2 3518/4885ADORA2A 203/4885 |
| US-20250066364-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | ALOX5 685/4885EPHX2 3518/4885ADORA2A 203/4885 |
| US-11091492-B2 | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | PARK7, PNP, GAA | ALOX5 685/4885EPHX2 3518/4885ADORA2A 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.